Skip to main contentGIST treatment in Ahmedabad and Gandhinagar · Dr Harsh Shah · Gastro & Cancer Surgeon · Apollo Hospital, Bhat, Gandhinagar and Gota OPD, Ahmedabad
A GIST — gastrointestinal stromal tumour — is treated along a pathway, not by a single operation. A contrast CT and an endoscopy, with endoscopic ultrasound for the stomach and duodenum, define the lump; a biopsy is taken only when the result will change what is done. For most GISTs that can be removed safely, surgery comes first, removing the tumour whole with a clear margin and without breaking it. Where the location would cost a valve, the sphincter or a large organ, imatinib tablets are given first to shrink it. After removal, the tumour’s size, cell-division rate, site and any rupture decide whether imatinib is needed afterwards. Advanced GIST is treated with tablets matched to the tumour’s mutation, and an operation is used only for selected situations.
Shah’s Gastro, Cancer & Robotic Surgery Centre
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Gastro & Cancer Surgeon
· Apollo Hospital, Bhat, Gandhinagar · Gota OPD, Ahmedabad
Dr Harsh Shah has 18 years of experience in gastrointestinal and cancer surgery, qualified twice over in surgical gastroenterology. GIST care needs more than an operating theatre, and at Apollo Hospital, Bhat the whole pathway sits together: endoscopy and endoscopic ultrasound with guided biopsy, pathology with the special stains and mutation testing that GIST needs, the medical oncology team for imatinib and the later tablets, keyhole and open surgery, and CT follow-up — with every case that may need tablets before or after surgery discussed by the tumour board. Google rating 4.89 from 216 reviews at the Gota clinic, and 4.94 from 17 reviews at the Apollo, Bhat listing.
A GIST is a tumour that grows from the wall of the gut, beneath its lining, most often in the stomach and next in the small intestine. It is a different disease from the common stomach cancer that starts in the lining: it rarely spreads to lymph nodes, it is not treated with ordinary chemotherapy, and it is driven in most patients by a mutation that a targeted tablet — imatinib — can switch off. That is why its treatment is planned on different rules.
Many GISTs are found by chance, as a smooth bump under normal lining on an endoscopy or a mass on a CT done for something else. Others announce themselves by bleeding — black stools, vomiting blood, or anaemia that will not correct — or by a lump, a blockage, and occasionally by bursting into the abdomen, which is a surgical emergency. Not every lump under the lining is a GIST, so sorting that out is the first job.
| Lump in the gut wall | How it is told apart | Usual treatment |
|---|---|---|
| GIST | Endoscopic ultrasound shows it in the muscle layer; the biopsy stains positive for KIT (CD117) and DOG1 | The pathway on this page — surgery, imatinib, or both |
| Leiomyoma or schwannoma | Similar on imaging, but different stains on the biopsy | Benign; many are watched, some removed — not treated as GIST |
| Stomach cancer (adenocarcinoma) | Starts in the lining, visible and biopsied directly at endoscopy | A cancer gastrectomy with lymph node removal, often with chemotherapy — a different pathway |
| Lymphoma or neuroendocrine tumour | Distinguished on biopsy and its special stains | Their own pathways — lymphoma is treated mainly with medicines |
A contrast CT of the abdomen and pelvis comes first, measuring the tumour in three planes and looking for spread to the liver or the lining of the abdomen. An endoscopy, with endoscopic ultrasound for the stomach and duodenum, then maps exactly where it sits. A biopsy is taken — through the endoscopic ultrasound, never through the skin for a tumour that can be removed — only when the result will change the plan. Before any imatinib for advanced or high-risk disease, mutation testing is done.
| Order | Test | What it answers |
|---|---|---|
| First | Contrast CT of the abdomen and pelvis | Size in three planes, the organ and exact site, its relation to the junction with the food pipe, the stomach outlet, the bile-duct opening or the anal canal, signs of rupture, and any spread to the liver or the abdominal lining |
| Second | Endoscopy, with endoscopic ultrasound for stomach and duodenal lumps | Which layer of the wall it grows from, its distance from the valves, and any worrying features such as an irregular edge or cystic spaces |
| Only if it changes the plan | Biopsy through endoscopic ultrasound (core or fine-needle) | Confirms GIST with KIT/CD117, DOG1 and CD34 stains, and a SDHB stain. A biopsy through the skin of a removable tumour is avoided, because it risks rupture and seeding along the needle track |
| Before tablets | Mutation testing of KIT and PDGFRA | Chooses the drug and the dose — one KIT mutation needs a higher imatinib dose, and one PDGFRA mutation does not respond to imatinib at all and needs a different drug |
| Alongside | Blood counts, kidney and liver tests, albumin, a nutrition screen and fitness assessment | Bleeding GISTs often leave anaemia; poor nutrition is corrected before surgery. MRI is added for rectal GIST or an unclear liver spot; PET-CT is not routine |
One practical point. A very small, smooth lump in the stomach, under about two centimetres, with no worrying features on endoscopic ultrasound, does not always need a biopsy or an operation straight away — it can be followed with endoscopic ultrasound at planned intervals, and removed if it grows or changes. That surveillance applies to the stomach only; small lumps elsewhere in the gut are assessed more actively.
After removal, every GIST is graded on four facts: its size, its rate of cell division under the microscope, where in the gut it arose, and whether it ruptured. A ruptured tumour is high-risk whatever its size. These four facts decide whether imatinib is needed after surgery, and the mutation decides which drug and what dose.
Two of these are worth understanding because families find them surprising. Site matters: a GIST of the same size and division rate is more likely to come back from the small intestine than from the stomach. And rupture changes everything: a tumour that bursts — before surgery, or by being broken or cut into pieces during it — moves to the highest-risk group. That is why the operation itself is planned around never breaking the tumour.
The mutation sorts GIST into families that behave differently. Most carry a KIT mutation and respond to imatinib. A smaller group carry a PDGFRA mutation, and one particular PDGFRA change makes the tumour resistant to imatinib so that a different targeted drug, avapritinib, is used. A further group lack the SDH enzyme; these respond poorly to tablets, grow slowly, can spread to lymph nodes, and need lifelong follow-up. The pathology report and the mutation result are therefore read together before any tablet is started.
GIST treatment is matched to the stage of the disease. A tumour that can be removed whole, without sacrificing an important organ, is operated on first. One in an awkward place is shrunk with imatinib first. After surgery, imatinib is added only for intermediate- or high-risk tumours, by the four facts and the mutation. Advanced or spread disease is treated with tablets in a set order, and surgery is added only for selected situations.
| Situation | Treatment | Why |
|---|---|---|
| Very small stomach lump without worrying features | Endoscopic ultrasound surveillance | Most such lumps stay still; removal if it grows or changes |
| Removable GIST in a straightforward site | Surgery first — wedge or segmental removal with a clear margin, tumour unbroken | Removing it whole is the treatment; no lymph node clearance is routinely needed |
| GIST at the junction with the food pipe, around the bile-duct opening in the duodenum, low in the rectum, or too large to remove safely | Imatinib first, usually for six to twelve months, then surgery once the response has levelled off | Shrinking first can save the valve, the pancreas head or the sphincter, and reduces the rupture risk |
| After removal — intermediate or high risk | Imatinib after surgery, three years for high risk; individualised for intermediate | Lowers the chance of the tumour returning while the tablet is taken |
| After removal — very low or low risk, or an imatinib-resistant mutation, or SDH-deficient | No tablets after surgery; CT follow-up | The tablet adds side effects without benefit in these groups |
| Advanced or spread GIST | Tablets matched to the mutation: imatinib first (a higher dose for one KIT mutation; avapritinib for the resistant PDGFRA mutation), then sunitinib, regorafenib and ripretinib in turn if the disease progresses | Each line is used until it stops working; tablets, not ordinary chemotherapy, are the backbone |
| Spread GIST responding to tablets, with a few remaining spots, or one spot growing while the rest respond, or a complication such as bleeding | Surgery added to the tablets | Selected removal can help; surgery is never the answer to disease growing everywhere |
Surgery is not the right first step for every GIST. A very small, quiet stomach lump can be watched. A tumour in a difficult position is shrunk with tablets first. Spread disease growing in many places is treated with tablets alone, because operating does not help it. And after a complete removal, a low-risk tumour needs follow-up scans, not more treatment.
Two situations need particular care. A tumour that is responding to imatinib should not have the tablet stopped — interrupting it allows the disease to grow again, so imatinib for spread GIST is continued, with surgery planned around it rather than instead of it. And if the edge of a removed tumour is found to be involved under the microscope after a wedge removal, a second operation is not automatic; the tumour board weighs it case by case.
Imatinib works only if it is taken every day, and the tablet must be genuine. Response is judged on CT by how the tumour's density changes, not only by its size — a tumour that turns darker and cyst-like on imatinib is usually responding, even if it has not shrunk. Side effects such as puffiness around the eyes, muscle cramps and low blood counts are managed, and the tablet is never stopped silently.
When a GIST seems to grow on imatinib, the first questions are practical: are the tablets being taken every day, and are they genuine? Counterfeit generic tablets are a real problem, and adherence is checked before anyone concludes that the tumour has become resistant. If it truly has, the next tablet in the sequence is started — resistance is the tumour’s biology, not the patient’s fault. Blood counts and liver tests are checked regularly on treatment, and any side effect that troubles you is a reason to call, not a reason to stop the tablet on your own.
Surgery for GIST removes the tumour whole, with a margin of normal wall around it, and preserves as much of the organ as possible. Most stomach GISTs need only a wedge of stomach wall; small-intestine GISTs need a short segment removed and rejoined. Lymph nodes are not routinely removed. The one absolute rule is not to break the tumour.
Stomach. A wedge removal of the stomach wall, by keyhole surgery — laparoscopic or robotic — for smaller tumours in favourable positions, and open surgery for large tumours, those at risk of rupture, or emergencies. A tumour on the back wall may need an endoscope passed during the operation to locate it. Near the food-pipe junction or the stomach outlet, the closure is planned so the passage does not narrow. A larger stomach operation is done only when a wedge cannot keep the passage open. For selected small tumours in awkward places, an endoscope and keyhole surgery can be used together. A purely endoscopic removal is not the standard approach for most GISTs, because a broken capsule cannot be rescued from inside the stomach.
Duodenum, small intestine and rectum. Duodenal GISTs are removed with a wedge or short segment where the bile-duct opening can be safely kept, after imatinib shrinkage where it is close; a larger pancreas-and-duodenum operation is kept for when it cannot. Small-intestine GISTs are removed as a short segment and rejoined. Rectal GISTs are treated function-first: imatinib, then the least destructive removal that clears the tumour, with removal of the anal canal only when the sphincter cannot be freed.
During keyhole surgery the tumour is never grasped directly — it is handled by the wall beside it — and every specimen comes out in a retrieval bag. If the tumour cannot be removed safely through small incisions, the operation is converted to open rather than risk a rupture.
The complications every patient hears about before agreeing: bleeding; wound infection; clots in the legs or lungs; heart and anaesthetic complications; conversion to open surgery; a leak or bleeding from the stomach closure; narrowing near the food-pipe junction or the stomach outlet; slow stomach emptying; rupture of the tumour capsule despite every precaution, which moves the disease into the high-risk group; a larger stomach operation decided during surgery; the tumour returning, depending on its final risk group; and a risk to life. After surgery there may be imatinib for three years, with its own side effects. Dr Harsh Shah goes through each of these personally before consent, with the figures that apply to your tumour’s site and size and to your own health — they are not general numbers and are not quoted on a page.
A patient describes recovery after stomach cancer surgery with Dr Harsh Shah (in Hindi). It is shared to show the recovery and follow-up at this centre; it is not a GIST patient’s account.
GIST surgery and the tablets are covered by cashless health insurance and by CGHS and corporate schemes at Apollo Hospital, Bhat, subject to the policy's terms. What moves an estimate is the operation needed, keyhole or open, the length of stay, mutation testing, and whether imatinib is needed before or after surgery and for how long. A written estimate is prepared for your own policy rather than a figure being quoted in general.
Pre-authorisation is arranged by the hospital’s insurance desk, with a note from Dr Harsh Shah’s office describing the diagnosis and the planned treatment. Because imatinib may continue for years, ask the desk early how your policy treats long-term oral cancer tablets, and buy the tablets only from a verified source. Bring policy papers, identification and every report.
★★★★★
“We are very thankful to Dr. Harsh Shah for treating and operating on my father for gastric (stomach) cancer. From the first consultation to the surgery and follow-up, he guided us with great care and explained everything clearly. My father is doing well now, and we are extremely grateful for the treatment and support provided by Dr. Harsh Shah and his team. He is a highly experienced and compassionate doctor. We would definitely recommend Dr. Harsh Shah to anyone looking for an experienced doctor for stomach cancer treatment. Thank you, Doctor, for everything! — Moh. Ahsan, Google review, Apollo, Bhat listing”
★★★★★
“My father has carcinoma of stomach ,Harsh sir did radical gastrectomy and he is recovering very nicely under Dr.Harsh's observation ,he listen each and every complain calmly and with patience and make patient very comfortable during treatment , during procedure and during stay at hospital. we are satisfied with the treatment and very confident about the fully recovery of disease as we are under treatment of Dr.Harsh & team.Thank you Dr.Harsh & his whole team and staff. — tina parmar, Google review, Gota clinic listing”
★★★★★
“Excellent doctor for stomach cancer. We r very happy. Recommend for gastro cancer treatment in Ahmedabad — Purshottam Meena, Google review, Shah's Cancer & Robotic Surgery Centre listing”
Real Google reviews from Dr Harsh Shah’s two listings, reproduced exactly as written.
A GIST is a tumour that can behave anywhere from almost harmless to aggressive, and it is treated within cancer care. Its behaviour is judged after removal by its size, cell-division rate, site and whether it ruptured, which together decide whether more treatment is needed.
Ordinary chemotherapy does not work for GIST. The medicine used is a targeted tablet, most often imatinib, chosen by the tumour's mutation. Many patients with a completely removed low-risk GIST need no tablets at all.
Not always. A very small, smooth stomach lump with no worrying features on endoscopic ultrasound can be followed with repeat scans and removed if it grows or changes. Lumps outside the stomach, or with worrying features, are assessed more actively.
For a tumour that can be removed, a needle through the skin risks bursting it or seeding cells along the needle track, which makes the disease high-risk. When tissue is needed, it is taken through endoscopic ultrasound from inside the gut.
After surgery for a high-risk GIST, the standard is three years. For advanced or spread disease, imatinib is continued for as long as it keeps working, because stopping it lets the tumour grow again.
It decides the drug and the dose. One KIT mutation needs a higher imatinib dose, one PDGFRA mutation does not respond to imatinib and needs avapritinib, and some GISTs gain nothing from the tablet after surgery.
Shah’s Gastro, Cancer & Robotic Surgery Centre
Gota, Ahmedabad, Gujarat
Google rating 4.89 from 216 reviews
Dr Harsh Shah consults at two addresses: the clinic at Gota, Ahmedabad, and Apollo Hospital at Bhat, Gandhinagar.
Patients come to Dr Harsh Shah from across Gujarat and from Rajasthan and Madhya Pradesh. The work-up, the operation and the review of the final pathology happen here; the follow-up CT scans can often be done closer to home and reviewed here.
Told there is a "lump in the stomach wall" on an endoscopy or CT? The CT, the endoscopy and endoscopic ultrasound reports, and any biopsy or pathology report can be sent ahead of the appointment so the consultation starts with them already read; the treatment itself is decided at the consultation, after examination. Call +91-63555-64601 · Send the reports ahead on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
